# Hitachi High-Tech



# **Analytical & Medical Solutions Business Briefing**

June 26, 2019
Hitachi High-Technologies Corporation
Analytical & Medical Solution Business Group

#### **Key Messages Today**



#### 1. FY2018 Performance

Record high revenues: 206.4 billion yen,

EBIT margin: 14% (Science & Medical Systems)

#### 2. Aiming to Pursue Social Value and Business Value

Realize a sustainable society EBIT margin: 15% or more

#### 3. Engines Supporting Business Growth Strategy

Focused Solutions (FS)

System Collaboration Business (SCB)

Global manufacturing system

Global sales and digital marketing

**Business** investment

#### 4. Focused Solutions


Introducing dedicated equipment to meet customer needs



# FY2018 Performance (Science & Medical Systems) Inspire the Next







# Reinforcing Resources and Investment in 2018 Mid-Term Management Strategy



# Science & Medical Systems results

(FY2016-2018 cumulative)

R&D:

40.6 billion yen

Capital investment:

17.1 billion yen

**Business investment:** 

15.1 billion yen

Strengthened analyzer lineup and global sales network

Acquired stock and partial business from Oxford Instruments plc Group in the UK

Developed new products and related technologies in the biotechnology and medical field

Promoted joint creation with universities, research institutions and overseas companies, as well as close development with customers

Reinforced manufacturing in the medical field


Advanced new business development, including entry into cancer diagnostic field

Capital participation in MagArray, Inc. and OmniSeg®, Inc. in the US






# Contribute to the realization of a sustainable society through the Analytical & Medical Solutions Business





## **Changes in Business Management System**









### **Analytical & Medical Solutions**


Create new value in the fields of Bio/Medical, analysis, etc., by utilizing "analysis technology"



### **Target: Secure Profitability**



- →Business management with profitability as a KPI
- →Organic business growth + M&A



(Calculated by restating the results for Science & Medical Systems within the scope of Analytical & Medical Solutions)





## **Provide Focused Solutions (FS)**



Develop general-purpose products into dedicated products to meet customer needs and create markets


General-purpose >>> Provide dedicated equipment/solutions (FS) >>> Create niche markets

Medical sophisticated Automation/control technolog FS Bio **Observation** manufacturing **Analysis** (Focused **Individualized** SECURITY Environmental Conservation Measurement customer needs capabilities Solutions) and **Advanced ENERGY** HEALTH CARE **Materials Analysis** Quality Contamination Testina **Testing** 



FS to meet "customer needs at the point of change in era"


→ Create new niche markets



## **System Collaboration Business (SCB)**



Open innovation for developing best solutions (strong equipment + strong reagents) for customers through equal business partnerships with strong reagent companies



Roche: Roche Diagnostics

Themo: Thermo Fisher Scientific Inc.

Qiagen: QIAGEN N.V.

Promega: Promega Corporation



## **Global Optimization of Manufacturing**



Globalization of development and manufacturing

→Reducing costs, utilizing skills, policy response, etc.

Japan (Oyama, Shizuoka Pref.)

Hitachi High-Tech Science Corporation
• Analyzers

#### Finland, Germany, and China

Hitachi High-Tech Analytical Science Ltd.

· Analyzers (compact field products)

#### Japan (Hitachinaka, Ibaraki Pref.)

Hitachi High-Technologies Corporation

- Clinical analyzers (large-sized)
- Hitachi High-Tech Science Corporation
- Analyzers

#### China

Hitachi Instruments (Dalian) Co., Ltd.

Analyzers

#### US

Hitachi High-Technologies Science America, Inc.

Analyzers (X-ray detectors)

#### China

Hitachi Instrument (Suzhou), Ltd.

Clinical analyzers

#### Japan (Omuta, Fukuoka Pref.)

Hitachi High-Tech Kyushu Corporation

- Clinical analyzers (small-sized)
- Consumables



### **Strengthen Global Sales**




#### Maximum use of sales & service network acquired through M&A

→(HHS) and (HHA) to provide sales and services for both companies' products in their respective areas

(HHS): Hitachi High-Tech Science Corporation

(HHA): Hitachi High-Tech Analytical Science Ltd.



#### China Main sales entity: (HHA)

- Reorganize and integrated multiple business companies
- Bolster product lineup

#### Europe and the US Main sales entity: (HHA)

- Expand sales of (HHS) products
- Promote acquisiton of CE\* mark
- Web marketing mainly driven by Europe and the US



- Concentrate resources at key agencies and reinforce sales capability
- Expand sales of (HHA) products in Japan

<sup>\*</sup>CE mark: A symbol indicating compliance with EU safety standards, required for products sold in Europe



#### HITACHI Inspire the Next

### **Strengthen Sales Capability through Digital Marketing**



#### **Continuous Business Investment**



Business investment: Approx. 15.1 billion yen (FY2016–2018)

# Accumulate experience of M&A and PMI\*

**Japan** 

**Hitachi High-Tech Science Corporation** 



**Global** 

Hitachi High-Tech Analytical Science Ltd.

## Continuous and proactive investment



**Target** 

High growth biotechnology and medical products business Core analysis business Cutting-edge technologies / Foundation technologies for FS

Strengthen existing business functions

Global sales Strengthen lineup Create new value

Diagnostic solutions
Sensitivity, Miniaturization, Acceleration

**Creativity for FS** 

Data processing, AI, automation, robotics





#### **Basic Policy of Bio and Medical Systems Business**



**Medical market** 

Likely to remain brisk, expect growth in emerging markets to continue

CAGR: 2-4%

Biotechnology market

Strong growth in genetics-related areas

CAGR: 4-12%

Become a global player in all in-vitro diagnostics markets

Realize a healthy society through IVD\*

- Maintain and expand top share in clinical chemistry and immunodiagnostic analyzers
- Expand business into new in-vitro diagnostic fields
- Develop next-generation genetic analysis products
- Expand the bio business scope through new entry



<sup>\*</sup>IVD: In-Vitro Diagnostics, In-vitro diagnostic clinical equipment

## Further Growth in Existing Business: Roche (SCB)





Daily maintenance "0" minutes (clinical chemistry module section)

Long-term continuous use of reagent (up to 6 months)

Next-generation global standard for medium- to large-sized facilities



Streamlining and labor-saving for testing operations in line with global optimization of medical fees





### Further Growth in Existing Business: Roche (SCB)



cobas e801

World's fastest and largest level\* of throughput
Dramatically improved operability
Reagent change possible during measurement operation, etc.

\*Depend on the module configuration





Respond to the increase in samples and high sensitivity in line with the increase in the demand of immunoassay testing 24-hour non-stop operation



#### **Expand Business Field: Blood Coagulation Testing**



3500

The world's first multifunction device\* for clinical chemistry, immunoassay, and blood coagulation testing Enables faster testing and more efficient clinical testing operations

\*Hitachi High-Technologies investigation





Improve operation of multiple devices by a small number of operators at ER departments and small- to mediumsized clinics





#### **Pre-Processing Automation with Robots**



Humanoid robots offer high versatility and flexibility







FUTURE Reduce testing laborators Reduce testing laboratory operation costs





# Genetic Analysis

**Sanger DNA sequencers** 

**Next-generation DNA** sequencers/ **Collaboration with** universities

Low-throughput Mid-throughput

High-throughput

Joint research lab with Keio University



Completed product image





©Thermo Fisher Scientific





Provide genetic analysis systems and molecular diagnostic solutions



**Expansion in fields of application for genetic** testing (Research, diagnostics, DNA tests, etc.) **Expectation for equipment for easy use,** simplicity and reliability



# FS for IVD Market Microbiology Testing



Verigene System®

**Multiplex Sepsis test covered by National Health Insurance:** 

1,700 points (=17,000 JP Yen)

Blood culture gram positive (BC-GP)

**Blood culture gram negative (BC-GN)** 

Microorganism and Antimicrobial resistance genes identified within 2.5 hours for early diagnosis of Blood Stream Infection





For patient, improve Quality of Life (early diagnosis and appropriate antibiotics therapy) For hospital, reduce medical expenses (avoid unnecessary antibiotics administration and minimize length of patient's stay at hospital)





\*Verigene® is a registered trademark of US company Nanosphere, Inc. in Japan.

# MagArray

Trace amount biomarker testing using ultra high sensitivity detection technology

Started lung cancer screening test business (2018)





Growing needs for diagnosis to determine treatment policy for cancer diagnosis and effective testing methods for companion diagnosis



## **Basic Policy of Analytical Systems Business**



Analytical market

Robust demand for general equipment, growth in dedicated industrial measurement equipment

CAGR: 3-4%

Become a major global player in analytical instruments markets

Realize a safer and more secure society

- Provide solutions for each field
- Launch new strategic products
- Strengthen global sales and service system



# LIBS Vulcan+



Rapid onsite testing, easy operation, and toughness

# XRF Optical X-MET8000 Emission





# Optical Emission Spectrometers

Handles a wide range of metal elements with complete mobility





Quality Testing


Rapid analysis in the field for metal manufacturing and recycling quality management



## FS for Quality Testing Data Management Solutions



## Cloud data service





Centralized management of multiple measurement on-site data using cloud systems

Quality Testing

**Centralized management of** measurement data by quality controllers











Automatic, NDI (Non-Destructive Inspection) of trace contaminants and element identification Contribute to development and quality management of next-generation batteries







Structure of a fuel cell

Contaminant Testing Improved yields of lithium-ion rechargeable and fuel cell batteries
Identification of trace metal contaminants that cause heating and fires



# FS for the Environment Phthalates Screening



# HM1000A

Onsite rapid screening test (10 minutes or less)

Combine cloud systems and Al to increase analysis **functions** 













High-speed, simple, low-cost measurement of substance restricted under revised RoHS Directive Increase screening test accuracy





## **FS for Mass Spectrometry Technology**



Mass spectrometry technology



Example:
One of the world's smallest mass spectrometers



#### For clinical testing



Contribute to early diagnosis and accurate treatment





#### For phthalate scanning



Comply with revised RoHS Directive





#### For security



Contribute to a safe, secure society



**FS (Focused Solutions)** 



# LA8080 AminoSAAYA

Firm position as a leader in high data reliability since its launch in 1962




Quality Testing Increase in needs ranging from analysis of umami components in food to research and quality-control for health supplements, biotech and pharmaceutical products.



#### Policy for Reinforcement and Investment of Resources





# Hitachi High-Tech





# Science for a better tomorrow

**Key Messages Today** 

#### 1. FY2018 Performance

Record high revenues: 206.4 billion yen,

EBIT margin: 14% (Science & Medical Systems)

#### 2. Aiming to Pursue Social Value and Business Value

Realize a sustainable society

EBIT margin: 15% or more

#### 3. Engines Supporting Business Growth Strategy


FS, SCB, global manufacturing system, global sales, digital marketing, business investment

#### 4. Focused Solutions

Introducing dedicated equipment to meet customer needs

#### **Appendix: Organization and Structure**







#### Notes on the data



- 1. All financial statement summaries and results predictions included in this presentation are on a consolidated basis unless otherwise stated.

  Numerical data is rounded off to the nearest 100 million yen.
- 2. In its disclosures, Hitachi High-Technologies may make statements that constitute forward-looking statements that reflect management's views with respect to certain future events and financial performance at the time of disclosure. Such statements are based on information available at the time of disclosure and may differ from actual results due to various external factors, both direct and indirect. In the event of a major discrepancy with the items disclosed, the Company will disclose on a case-by-case basis based on the law and/or the timely disclosure rules and regulations of the stock exchanges on which the Company is listed.

The information included in this material is for reference when investing, and not a canvass to invest. Brand selection and the final decision is at your own judgment.

For further information Mitsuru Kuwabara

General Manager, CSR & Corporate Communications Dept., CSR Div.

TEL: +81-3-3504-5138 FAX:+81-3-3504-5943

E-mail: mitsuru.kuwabara.ya@hitachi-hightech.com

